rufutalkib   Click here for help

GtoPdb Ligand ID: 14634

Synonyms: Example 10 [WO2014071832] | SAF-189 | SAF-189s
Compound class: Synthetic organic
Comment: Rufutalkib is the INN for an anaplastic lymphoma kinase (ALK) inhibitor, that was included in WHO INN Proposed List 135 (July 2026). There is a structure match for a compound claimed in patent WO2014071832A1 [2]. Online resources suggest that Fochon Pharmaceutical's lead ALK and ROS proto-oncogene 1 (ROS1) kinase inhibitor SAF-189 is also named foritinib, however this is not a bona fide INN. It is likely that rufutalkib is the proposed INN for SAF-189. SAF-189 is intended as an orally bioavailable anti-tumour agent wit potential to overcome crizotinib resistance [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 103.77
Molecular weight 570.15
XLogP 3.27
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)S(=O)(=O)C1=C(C=CC=C1)NC2=C(C=NC(=N2)NC3=CC(=C(C4CCN(C)CC4)C5=C3O[C@H](C)C5)C)Cl
Isomeric SMILES C[C@@H]1CC2=C(C(=CC(=C2O1)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl)C)C5CCN(CC5)C
InChI InChI=1S/C29H36ClN5O3S/c1-17(2)39(36,37)25-9-7-6-8-23(25)32-28-22(30)16-31-29(34-28)33-24-14-18(3)26(20-10-12-35(5)13-11-20)21-15-19(4)38-27(21)24/h6-9,14,16-17,19-20H,10-13,15H2,1-5H3,(H2,31,32,33,34)/t19-/m1/s1
InChI Key RAQWCVHUHOLULM-LJQANCHMSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Bioactivity Comments
Anti-proliferative and anti-tumour activities are reported in [2], but we have been unable to locate quantitative data for target kinase inhibitory activity.